Oncology /
Immunology
Immunology
Gene therapy
Platform
Platform
In vivo CAR-T Virus-like particle Fusogen
Thesian is at the forefront of developing a cell-specific in-vivo CAR-T therapy to treat both liquid and solid tumors, as well as autoimmune disorders.
Our innovative gene therapy platform utilizes a locked virus-like particle (VLP) that requires a specific co-receptor expressed on CD4 and CD8 T-cells. This mechanism unlocks the fusogen and delivers the CAR payload, significantly minimizing off-target effects.
This approach has the potential to surpass traditional ex-vivo methods by offering an off-the-shelf therapy that enhances CAR-T cell efficacy without the need for conditioning chemotherapy.
Our innovative gene therapy platform utilizes a locked virus-like particle (VLP) that requires a specific co-receptor expressed on CD4 and CD8 T-cells. This mechanism unlocks the fusogen and delivers the CAR payload, significantly minimizing off-target effects.
This approach has the potential to surpass traditional ex-vivo methods by offering an off-the-shelf therapy that enhances CAR-T cell efficacy without the need for conditioning chemotherapy.
Rémi Soula
Partner & EIR
Rémi Soula, Founding Partner and Entrepreneur in Residence at Argobio, co-founded Adocia (Euronext Paris: ADOC), a French public biotech company, where he was head of Business Development and Legal Affairs. Over his 14 years at Adocia, he has been in charge for several large licensing deals and partnerships with pharmaceutical companies in the US and China, and he has actively participated to the financing rounds and the IPO of the company. Prior to Adocia, he was Senior Manager at Avadel Pharmaceuticals (NASDAQ: AVDL, formerly Flamel Technologies SA). He has also been on the board of several companies, including Cellnovo. (Euronext: CLNV), a former French public medtech company. He is co-inventor on more than thirty patent families. Rémi holds a PhD in Chemistry from University Claude Bernard Lyon 1 and an executive MBA from HEC Paris.